Unraveling systemic inflammatory responses to mRNA-LNPs

Charlotte Barker, Editor, Vaccine Insights, speaks with Siri Tähtinen, Principal Scientist at Genentech, a member of the Roche Group, about developing immunotherapies and vaccines for the treatment of autoimmune, inflammatory, and malignant diseases. They discuss inflammatory responses to mRNA-LNPs and the delicate balance between reactogenicity and immunogenicity.  

Please enter your email to access content Read now